1. Home
  2. QCRH vs ABCL Comparison

QCRH vs ABCL Comparison

Compare QCRH & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo QCR Holdings Inc.

QCRH

QCR Holdings Inc.

HOLD

Current Price

$106.56

Market Cap

1.7B

Sector

Finance

ML Signal

HOLD

Logo AbCellera Biologics Inc.

ABCL

AbCellera Biologics Inc.

HOLD

Current Price

$11.37

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
QCRH
ABCL
Founded
1993
2012
Country
United States
Canada
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.6B
IPO Year
1996
2020

Fundamental Metrics

Financial Performance
Metric
QCRH
ABCL
Price
$106.56
$11.37
Analyst Decision
Buy
Strong Buy
Analyst Count
4
5
Target Price
$98.25
$8.40
AVG Volume (30 Days)
96.8K
7.8M
Earning Date
04-22-2026
05-11-2026
Dividend Yield
0.44%
N/A
EPS Growth
11.62
10.91
EPS
4.18
N/A
Revenue
$165,999,610.00
$75,128,000.00
Revenue This Year
$8.46
N/A
Revenue Next Year
$5.59
$21.85
P/E Ratio
$25.50
N/A
Revenue Growth
20.72
160.56
52 Week Low
$66.71
$2.75
52 Week High
$106.68
$11.07

Technical Indicators

Market Signals
Indicator
QCRH
ABCL
Relative Strength Index (RSI) 69.84 83.57
Support Level $93.70 $3.38
Resistance Level $106.55 N/A
Average True Range (ATR) 1.95 0.74
MACD 0.13 0.62
Stochastic Oscillator 77.00 98.39

Price Performance

Historical Comparison
QCRH
ABCL

About QCRH QCR Holdings Inc.

QCR Holdings Inc is a multi-bank holding company. The bank operates through segments namely Commercial Banking, Wealth Management, and all other segments. The commercial bank segment is geographically divided by markets namely Quad City Bank & Trust (QCBT), Cedar Rapids Bank & Trust (CRBT), Community State Bank (CSB) and Guaranty Bank (GB). It generates revenue in the form of interest.

About ABCL AbCellera Biologics Inc.

AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.

Share on Social Networks: